Can Probiotics Help Treat and Fight Colon Cancer


A new study looks at the potential of probiotics in the prevention and treatment of colorectal cancer associated with inflammatory bowel disease. So far, the results – following tests in mice – are promising, but further investigation is required.

According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed type of cancer, excluding skin cancer, among adults in the United States. They also estimate that colorectal cancer may cause around 50,260 deaths in 2017.

Existing studies suggest that some of the leading factors for increased risk of colorectal cancer include having been diagnosed with inflammatory bowel disease, genetic factors, smoking, lack of physical activity, and a high body mass index (BMI).

According to recent investigations, the gut microbiome plays a key role in the development of colorectal cancer. However, many of the mechanisms at play still remain unclear. Some research suggests that using probiotics to influence the microbiome may help to prevent tumor formation.

A new study led by Dr. James Versalovic, a professor of pathology and immunology at Baylor College of Medicine in Houston, TX, now looks at whether certain probiotics may be used to prevent or treat colorectal cancer.

Dr. Versalovic and his colleagues focused on the role of Lactobacillus reuteri, which is a probiotic naturally found in the guts of mammals. This bacterium has been shown to reduce inflammation in the intestine, so the team was interested in testing its effect on colorectal cancer tumors.

Probiotics decrease tumor formation

In adult mice, it has been noted that the lack of an enzyme called histidine decarboxylase (HDC) made the animals significantly more susceptible to developing colorectal cancer associated with inflammation of the bowels.

HDC is produced by L. reuteri and helps to convert L-histidine, which is an amino acid with a role in protein synthesis, to histamine, which is an organic compound involved in the regulation of the immune response.

Dr. Versalovic and team tested the role of L. reuteri in regulating immune responses with a view to observing its potential in inhibiting colorectal cancer tumor formation.

They used HDC-deficient mice, to which they administered L. reuteri. They also administered a placebo compound to mice in the control group, in order to compare the effects.

L. reuteri was given to the mice once before, and once again after, the induction of tumor formation through the administration of azoxymethane, a carcinogenic chemical, and DSS, a substance that stimulates inflammation.

Fifteen weeks after this procedure, the mice’s gastrointestinal tracts were studied, to control for tumor progression and the effect of the probiotic.

The researchers found that L. reuteri stimulated the production of HDC and raised the levels of histamine in the colon.

Positron emission tomography was used to scan for tumors, and the researchers noted that the mice that had ingested the probiotic exhibited fewer tumors and of smaller sizes. Conversely, the animals from the control group had more, and larger, tumors.

Inactive strains of L. reuteri, which were HDC-deficient, did not exhibit any protective effects.

The researchers also noted that the probiotic (its active strain) was effective in reducing the inflammation stimulated by the chemicals – that is, DSS and azoxymethane – that had been administered to the mice.


Please enter your comment!
Please enter your name here